Vericel (VCEL) Projected to Post Quarterly Earnings on Thursday

Vericel (NASDAQ:VCEL) is anticipated to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.45 per share and revenue of $92.6640 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Vericel Price Performance

Shares of Vericel stock opened at $37.41 on Thursday. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of 155.88 and a beta of 1.24. The stock’s 50-day moving average is $36.93 and its 200-day moving average is $36.08. Vericel has a one year low of $29.24 and a one year high of $58.16.

Institutional Investors Weigh In On Vericel

Large investors have recently bought and sold shares of the company. AQR Capital Management LLC bought a new stake in shares of Vericel during the first quarter worth $242,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Vericel by 6.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,445 shares of the biotechnology company’s stock valued at $1,403,000 after acquiring an additional 1,847 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Vericel by 13.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 371,486 shares of the biotechnology company’s stock valued at $16,576,000 after acquiring an additional 44,333 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Vericel by 9.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,028 shares of the biotechnology company’s stock worth $5,490,000 after acquiring an additional 10,191 shares during the last quarter. Finally, Qube Research & Technologies Ltd increased its holdings in Vericel by 5.1% in the 2nd quarter. Qube Research & Technologies Ltd now owns 277,253 shares of the biotechnology company’s stock worth $11,797,000 after purchasing an additional 13,422 shares in the last quarter.

Wall Street Analyst Weigh In

VCEL has been the topic of a number of recent analyst reports. Truist Financial lowered their price target on Vericel from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a report on Sunday, January 25th. Zacks Research lowered shares of Vericel from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Vericel in a research note on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $57.50.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.